0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Wellbeing Digital Sciences
Its shares trade under the ticker KONEF. It has been listed since 27 January 2021. In the fiscal year to 31 July 2022, it reported revenue of C$6.4m and a net loss of C$25.2m. At that date it held total assets of C$17.2m and shareholders' equity of −C$229,260.
Wellbeing Digital Sciences, Inc. focuses on consolidating medical clinics and becoming a North American leader in mental health treatments. The company is headquartered in London, Ontario. The company went IPO on 2021-01-27. The firm is focused on the development and implementation of clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. The company operates through three segments: Wellbeing & IRP; KGK Science and Mindscape. The company operates medical clinics across North America to help its patients access plant-based medicines, psychedelics, and other forms of mental health care, all of which have the potential to heal them of their physical and/or emotional pain. Its subsidiaries include Mindscape Ketamine & Infusions Therapy LLC, KGK Science Inc. and Integrated Rehab and Performance Ltd. The company is also supported by a network of North American clinics that provide therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services with a focus on nutraceutical and emerging health care products.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 27 Jan 2021
- Website
- wellbeingdigital.co ↗
Leadership
Pay as last reported
- Ms. Najla GuthrieChief Executive Officer, Director, since 2021C$496,888
- Mr. Terry ZimaroChief Financial OfficerC$25,000
- Mr. Brendan PurdyIndependent DirectorC$62,022
- Ms. Natasha RaeyIndependent DirectorC$62,022
- Mr. Mohammad SharifiIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- North American clinics provide access to plant-based medicines for patients.
- Three segments include Wellbeing & IRP, KGK Science, and Mindscape.
- Subsidiaries offer ketamine therapy and integrated rehab services to clients.
Weaknesses
- Headquarters location in London, Ontario, may limit local operational flexibility.
- IPO date of 27 January 2021 indicates a relatively recent market entry.
- Reliance on emerging psychedelic medicine creates potential regulatory and safety uncertainties.
Opportunities
- Development of digital therapeutics supports expansion into modern mental health care.
- Clinical research backing enhances credibility for nutraceutical product offerings.
- Contract research organization services attract partners for emerging health care products.
Threats
- Strict regulations surrounding psychedelic medicine usage could hinder clinical operations.
- Competitors in the mental health sector may adopt similar treatment models.
- Evolving legal frameworks for plant-based medicines pose compliance risks for clinics.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.